# Epcoritamab in Previously Treated WM

> **NCT06510491** · PHASE2 · RECRUITING · sponsor: **Gottfried von Keudell, MD PhD** · enrollment: 20 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia
- B-Cell Lymphoproliferative Disorder

## Interventions

- **DRUG:** Epcoritamab

## Key facts

- **NCT ID:** NCT06510491
- **Lead sponsor:** Gottfried von Keudell, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-06
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06510491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06510491, "Epcoritamab in Previously Treated WM". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06510491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*